Mumbai-based pharma formulator making sterile injectables, ophthalmic/nasal drops, OSD tablets and nutraceuticals, with a Cephalosporin plant in Ethiopia serving 49+ export markets.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 15 | 15 | 16 | 16 | 16 | 16 | 17 | 35 |
| Reserves | 103 | 112 | 124 | 136 | 160 | 186 | 248 | 245 |
| Borrowings | 13 | 15 | 20 | 22 | 32 | 49 | 84 | 89 |
| Other Liabilities | 12 | 61 | 50 | 46 | 32 | 61 | 49 | 89 |
| Total Liabilities | 143 | 203 | 210 | 220 | 240 | 313 | 399 | 458 |
| AssetsFixed Assets | 32 | 30 | 65 | 64 | 62 | 64 | 64 | 67 |
| CWIP | 30 | 65 | 3 | 4 | 6 | 47 | 98 | 140 |
| Investments | 52 | 60 | 71 | 62 | 72 | 72 | 77 | 75 |
| Other Assets | 30 | 47 | 71 | 90 | 100 | 129 | 160 | 176 |
| Total Assets | 143 | 203 | 210 | 220 | 240 | 313 | 399 | 458 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 0 | 4 | 46 | 6 | 3 | -2 | 18 | 24 |
| Cash from Investing | -14 | -10 | -38 | -15 | 8 | -8 | -40 | -100 |
| Cash from Financing | 17 | 1 | 2 | 7 | -1 | 9 | 13 | 82 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | -19 | -6 | 9 | -2 | -1 | -8 | -29 | -76 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (60.9×) and current (25.9×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 41% growth and a 26× exit, ₹182 only delivers your return if you pay ₹501. The price is currently baking in 18% growth.
EPS grows 41%/yr for 5 years, then fades to 6% over 2, exits at 26×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 41.0% | 9.90 |
| FY28 | 41.0% | 13.96 |
| FY29 | 41.0% | 19.68 |
| FY30 | 41.0% | 27.75 |
| FY31 | 41.0% | 39.12 |
| FY32 | 23.5% ·fade | 48.32 |
| FY33 | 6.0% ·fade | 51.22 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.